Galactose-alpha-1,3-galactose (alpha-gal) epitope on engineered pancreatic ductal adenocarcinoma (PDAC) tumor lysate glycoconjugates (alpha-gal PDAC lysate)

The alpha-gal epitope, specifically Galalpha1-3Galbeta1-4GlcNAc-R, is a carbohydrate structure found on the cell surfaces of non-primate mammals but is notably absent in humans, who instead produce large quantities of natural anti-Gal antibodies (Galili, U., Expert Review of Vaccines, 2013). In the context of pancreatic ductal adenocarcinoma (PDAC), this epitope is engineered onto tumor lysate glycoconjugates to create a potent immunotherapeutic agent. The mechanism involves the binding of endogenous anti-Gal IgG antibodies to the alpha-gal epitopes on the vaccine, which triggers complement activation and opsonization. This facilitates the uptake of tumor antigens by professional antigen-presenting cells (APCs) through Fc gamma receptor-mediated endocytosis (Galili, U., Journal of Immunology, 2020). Consequently, the APCs migrate to lymph nodes and present tumor-specific peptides to T cells, stimulating a robust systemic immune response against the patient's cancer cells. This approach aims to convert the tumor's immunosuppressive environment into an immunostimulatory one, enhancing the efficacy of traditional treatments like surgery and chemotherapy (Hardacre, J. M., et al., Journal of Gastrointestinal Surgery, 2013).

Other names

Alpha-gal epitopeGalalpha1-3Galbeta1-4GlcNAc-RAlpha-galactosyl epitopeHyperAcute Pancreas vaccine componentAlpha-gal modified tumor antigens

Binding of natural anti-Gal antibodies to the alpha-gal epitope on tumor antigens, leading to Fc receptor-mediated uptake by antigen-presenting cells and subsequent T-cell activation.